NaviFUS Corp. (6872.TWO) Stock

6872.TWO logo

NaviFUS Corp.

6872.TWOTaiwan
Healthcare

Company profile

NaviFUS reported revenue of 10.48 million TWD for fiscal year 2025, down 61.9% from fiscal year 2024. Our analysis of its filings shows revenue shrinking from 22.48 million TWD in fiscal year 2023 to 10.48 million TWD in fiscal year 2025, 31.7% a year on average.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss widened from 95.13 million TWD in fiscal year 2024 to 148.46 million TWD in fiscal year 2025.
  • It spent 116.51 million TWD on research and development in fiscal year 2025, 11.1 times its revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

About NaviFUS Corp.

NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan. The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others. It also develops NAVIRFA, a navigation system that uses optical 3D surgical tracking technology to monitor the 3D position of the needle tip during ultrasonic interventional procedures. The company was founded in 2015 and is based in Taipei, Taiwan.

Leadership

  • Hao-Li Liu Ph.D. — Founder & Chief Technical Consultant
  • Jen Chen Ph.D. — Chief Strategy Officer, 70

How much revenue does NaviFUS make?

NaviFUS reported 10.48 million TWD in revenue for fiscal year 2025, down 61.9% from 27.53 million TWD in fiscal year 2024.

What companies are similar to NaviFUS?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Medimaging Integrated Solution Inc. (6796.TW), Crystalvue Medical Corporation (6527.TWO), Taiwan Biomaterial Co., Ltd. (6649.TWO), Diamond Biotechnology Co., Ltd (6815.TWO).

Has NaviFUS made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 82.80 million TWD; FY2022, a loss of 63.59 million TWD; FY2023, a loss of 65.73 million TWD; FY2024, a loss of 95.13 million TWD; FY2025, a loss of 148.46 million TWD. It reported a net loss in each of these 5 years.

How much does NaviFUS spend on research and development?

Research and development by fiscal year: FY2021, 55.90 million TWD; FY2022, 64.02 million TWD; FY2023, 58.93 million TWD; FY2024, 84.15 million TWD; FY2025, 116.51 million TWD.

Company Information

SectorHealthcare
IndustryTargeted Healthcare Equipment
HeadquartersTaipei, Taiwan
ExchangeTaipei Exchange
TimezoneAsia/Taipei (CST)

Contact & Links

Address
No. 246, Chengde Rd., Taipei, 103
Phone
886 2 2586 0560
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “NaviFUS Corp. (6872.TWO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/6872.TWO

LinkedInLinkedInXXYouTubeYouTube